Akston Biosciences Completes Series E Preferred Stock Financing
Akston Biosciences has completed its $7.6 million Series E financing, including the conversion of $2.5 million from Notes sold previously. The purchasers included those who had invested in prior rounds and new investors as well. Dr. Todd Zion, Akston’s co-founder, President and CEO said, “The continuing support from our current stockholders is very much appreciated and I am pleased to welcome many new investors as well. We will use the proceeds to continue applying our insulin engineering platform to Type 1 Diabetes prevention as well as ultra-long acting insulins for both human and veterinary applications.”